Kiran Mazumdar-Shaw

CIK: 0002034672

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (42.9%)

Compensation grants

Other (G, F, J, C, D, …)4 (57.1%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

BCAX

Bicara Therapeutics Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (7 total)

BCAX
Bicara Therapeutics Inc.
Jun 9, 2026
Award(A)
Stock Option (Right to Buy)
Direct
19.5K shares-
BCAX
Bicara Therapeutics Inc.
Jun 9, 2025
Award(A)
Stock Option (Right to Buy)
Direct
23.7K shares-
BCAX
Bicara Therapeutics Inc.
Sep 16, 2024
Conversion(C)
Indirect
324.6K shares-
BCAX
Bicara Therapeutics Inc.
Sep 16, 2024
Conversion(C)
Indirect
4.3M shares-
BCAX
Bicara Therapeutics Inc.
Sep 16, 2024
Conversion(C)
Indirect
432.7K shares-
BCAX
Bicara Therapeutics Inc.
Sep 16, 2024
Conversion(C)
Indirect
1.1M shares-
BCAX
Bicara Therapeutics Inc.
Sep 12, 2024
Award(A)
Stock Option (Right to Buy)
Direct
23.7K shares-

		Type	Shares	Price		Ownership
Jun 9, 2026	BCAX Bicara Therapeutics Inc.	Award(A) Stock Option (Right to Buy)	19,475	-	-	Direct
Jun 9, 2025	BCAX Bicara Therapeutics Inc.	Award(A) Stock Option (Right to Buy)	23,746	-	-	Direct
Sep 16, 2024	BCAX Bicara Therapeutics Inc.	Conversion(C)	324,552	-	$0	Indirect
Sep 16, 2024	BCAX Bicara Therapeutics Inc.	Conversion(C)	4,327,365	-	$0	Indirect
Sep 16, 2024	BCAX Bicara Therapeutics Inc.	Conversion(C)	432,736	-	$0	Indirect
Sep 16, 2024	BCAX Bicara Therapeutics Inc.	Conversion(C)	1,080,775	-	$0	Indirect
Sep 12, 2024	BCAX Bicara Therapeutics Inc.	Award(A) Stock Option (Right to Buy)	23,746	-	-	Direct

1-7 of 7 transactions

About Mazumdar-Shaw Kiran

Mazumdar-Shaw Kiran (SEC CIK 0002034672) files insider reports with the SEC as Director of Bicara Therapeutics Inc. (BCAX).

Signal8 holds 4 ownership filings by Mazumdar-Shaw Kiran (1 Form 3, 3 Form 4), filed between Sep 12, 2024 and Jun 10, 2026. Those filings report 7 transactions, from Sep 12, 2024 to Jun 9, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Mazumdar-Shaw Kiran's filings is in BOSTON, MA.

Recent filings by Mazumdar-Shaw Kiran

Jun 9, 2026: Grant or award of BCAX derivative securities (Form 4, code A).
Jun 9, 2025: Grant or award of BCAX derivative securities (Form 4, code A).
Sep 16, 2024: Conversions of BCAX shares (4 lines, Form 4, code C).
Sep 12, 2024: Grant or award of BCAX derivative securities (Form 4, code A).

Other insiders filing for Bicara Therapeutics Inc. (BCAX)

Cohlhepp Ryan, President, COO & Interim CEO
Larson Jennifer, Chief Financial Officer
Hyep Ivan, Chief Financial Officer
Mazumdar Claire, Chief Executive Officer
Bender Jeremy, Director
Oliger Christy J., Director

How to read Form 4 transaction codes